Post-CAR-T cell therapy presenting as proteinaceous lymphadenopathy
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and is often treated with chemotherapy, autologous stem cell transplant, and chimeric antigen receptor (CAR-T) cell therapy. Despite the increasing use of CAR-T therapy in various hematolymphoid malignancies, very little is known abou...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-03-01
|
| Series: | Human Pathology: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214330021000043 |